2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Fatty Acid Synthase (FASN)

Fatty Acid Synthase (FASN)

Fatty Acid Synthase (FASN)

Related Products

PDF 0.46 MB

Fatty Acid Synthase (FASN) is a multifunctional homodimeric enzyme protein, and it is the major enzyme required for the anabolic conversion of dietary carbohydrates to fatty acids. Fatty acid synthase catalyzes the conversion of acetyl-CoA and malonyl-CoA, in the presence of NADPH, into long-chain saturated fatty acids.

Human fatty acid synthase is a large homodimeric multifunctional enzyme that synthesizes palmitic acid. The unique carboxyl terminal thioesterase domain of fatty acid synthase hydrolyzes the growing fatty acid chain and plays a critical role in regulating the chain length of fatty acid released. Also, the up-regulation of human fatty acid synthase in a variety of cancer makes the thioesterase a candidate target for therapeutic treatment.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-RS04755
    Fasn Rat Pre-designed siRNA Set A
    		Inhibitor

    Fasn Rat Pre-designed siRNA Set A contains three designed siRNAs for Fasn gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Fasn Rat Pre-designed siRNA Set A
  • HY-RS04753
    FASN Human Pre-designed siRNA Set A
    		Inhibitor

    FASN Human Pre-designed siRNA Set A contains three designed siRNAs for FASN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    FASN Human Pre-designed siRNA Set A
  • HY-N7521
    Procyanidin C2
    		Inhibitor
    Procyanidin C2 (Procyanidine C2) is a lipid metabolism regulator and antioxidant with free radical scavenging activity. Procyanidin C2 down-regulates ACC, SREBP-1c, FAS, SCD-1 and PPARγ. Procyanidin C2 increases the level of phosphorylated AMPKα and inhibits the level of phosphorylated mTOR. Procyanidin C2 reduces lipid accumulation, alleviates oxidative stress, enhances fatty acid oxidation and improves mitochondrial function. Procyanidin C2 can be used in the research of non-alcoholic fatty liver disease.
    Procyanidin C2
  • HY-110354R
    UCM05 (Standard)
    		Inhibitor
    UCM05 (Standard) is the analytical standard of Lysipressin. This product is intended for research and analytical applications. UCM05 (G28UCM) is a fatty acid synthase (FASN) and filamentous temperature-sensitive protein Z (Ftsz) inhibitor. UCM05 inhibits fatty acid synthesis, viral replication, and Gram-positive bacterial growth. UCM05 binds to FtsZ GTP-binding sites, inhibits GTPase activity, and disrupts Z-ring localization. UCM05 can be used for the research of HSV-1/2 infection, HIV-1 infection, and Gram-positive bacterial infections[1][2][3].
    UCM05 (Standard)
  • HY-16244
    GW-300
    		Ligand
    GW-300 is a SREBP cleavage-activating protein (SCAP) ligand that can be used for the study of endocrinology and metabolic disease.
    GW-300
  • HY-175020
    QNX-10
    		Inhibitor
    QNX-10 is a fatty acid synthase (FASN) inhibitor (IC50 = 0.7 μM) with anticancer activity. QNX-10 exhibits potent FASN inhibition and cytotoxicity against colorectal and breast cancer cells. QNX-10 induces apoptosis and cell cycle arrest in S phase by upregulating the pro-apoptotic protein Bax and downregulating the anti-apoptotic protein Bcl-xL. QNX-10 can be used to investigate anticancer therapies targeting FASN enzymes.
    QNX-10
  • HY-170570
    PFM046
    		Inhibitor
    PFM046 is the antagonist for liver X receptor (LXR), that inhibits the activation of LXRα and LXRβ with IC50 of 2.04 μM and 1.58 μM. PFM046 inhibits the expression of SCD1 and FASN, upregulates the expression of ABCA1, and exhibits antitumor efficacy in mouse models.
    PFM046
  • HY-N0686R
    Pseudoprotodioscin (Standard)
    		Inhibitor
    Pseudoprotodioscin (Standard) is the analytical standard of Pseudoprotodioscin. This product is intended for research and analytical applications. Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides.
    Pseudoprotodioscin (Standard)
  • HY-172298
    (R,S,S,S)-Orlistat
    		Inhibitor
    (R,S,S,S)-Orlistat is a stereogenic derivative of orlistat (tetrahydrolipstatin; THL) (HY-B0218). (R,S,S,S)-Orlistat inhibits three Mycobacterium tuberculosis lipid esterases, Ag85C (KI: 16.43 μM), Rv3802 (EC50: 16.2 nM), and Pks13-TE.
    (R,S,S,S)-Orlistat
  • HY-167879
    (Rac)-NPD6433
    		Inhibitor
    (Rac)-NPD6433 is a racemate of NPD6433. NPD6433 is a triazenyl indole with broad-spectrum activity against all screening fungal strains. NPD6433 targets the enoyl reductase domain of fatty acid synthase 1 (Fas1), covalently inhibiting its flavin mononucleotide-dependent NADPH-oxidation activity and arresting essential fatty acid biosynthesis.
    (Rac)-NPD6433
  • HY-149540
    CTL-06
    		Inhibitor
    CTL-06 is an inhibitor of Fatty Acid Synthase (FASN) (IC50: 3 μM) and can induce apoptosis. CTL-12 blocks the cell cycle in the Sub-G1/S phase, upregulates the expression of caspase-9 and the apoptosis marker Bax, and downregulates the anti-apoptotic marker Bcl-xL. CTL-12 inhibits de novo lipogenesis, blocks the metabolic demands of tumor cells, and is commonly used in breast and colorectal cancer research.
    CTL-06
  • HY-N0083R
    Betulin (Standard)
    		Inhibitor
    Betulin (Standard) is the analytical standard of Betulin. This product is intended for research and analytical applications. Betulin (Trochol), is a sterol regulatory element-binding protein (SREBP) inhibitor with an IC50 of 14.5 μM in K562 cell line.
    Betulin (Standard)
  • HY-178958
    PPAR agonist 7
    PPAR agonist 7 is an orally active pan-PPAR agonist, demonstrating potent activation of all three subtypes, PPARα (EC50 = 1.51 μM), PPARδ (EC50 = 1.11 μM), and PPARγ (EC50 = 3.14 μM). PPAR agonist 7 significantly enhances glucose uptake in adipocytes while exhibiting minimal adipogenic activity. PPAR agonist 7 can suppress PPARγ Ser273 phosphorylation in white adipose tissue and upregulate insulin-sensitizing genes. PPAR agonist 7 does not cause weight gain or fluid retention in high-fat diet (HFD)/ Streptozotocin (HY-13753) (STZ)-induced type 2 diabetes mellitus (T2DM) models. PPAR agonist 7 has selective modulation of PPAR signaling pathways without activation of adipogenic gene programs. PPAR agonist 7 can be used for the study of diabetes.
    PPAR agonist 7
  • HY-149545
    1,3-Palmitin-2-docosahexaenoin
    		Inhibitor
    1,3-Palmitin-2-docosahexaenoin (1,3-Dipalmitoyl-2-docosahexaenoyl glycerol) is the isomer of triacylglycerol (TAG), in which docosahexaenoic acid (DHA) is located at the β position (sn-2) of the glycerol backbone. 1,3-Palmitin-2-docosahexaenoin inhibits fatty acid synthase and cholesterol metabolism enzymes, activates carnitine palmitoyltransferase (CPT) in liver mitochondria and promotes β-oxidation of fatty acids. 1,3-Palmitin-2-docosahexaenoin exhibits lipid metabolism regulating activity.
    1,3-Palmitin-2-docosahexaenoin
  • HY-176274
    FASN/SCD-IN-1
    		Inhibitor
    FASN/SCD-IN-1 is a Silybin (HY-N0779A) derivative, an orally active inhibitor of Fatty Acid Synthase (FASN)/Stearoyl-CoA Desaturase (SCD). FASN/SCD-IN-1 has shown in vitro activity in inhibiting lipid deposition, reducing FASN and SCD transcriptional levels, and exhibiting antioxidant, anti-inflammatory, and anti-fibrotic activities. FASN/SCD-IN-1 has demonstrated significant hepatoprotective effects in a rat model of acute liver injury. FASN/SCD-IN-1 ameliorates the pathological features of MASH liver, including steatosis, inflammation, and fibrosis in a mouse model of myeloproliferative steatohepatitis (MASH). FASN/SCD-IN-1 can be used to study MASH.
    FASN/SCD-IN-1
  • HY-155282
    FASN-IN-6
    		Inhibitor
    FASN-IN-6 (compound 44) is a potent fatty acid biosynthesis (FAB) inhibitor. FASN-IN-6 is an antibacterial agent with MICs of 1 μg/mL and 4 μg/mL for S. aureus ATCC 25923 and E. faecalis ATCC 29212, respectively.
    FASN-IN-6
  • HY-181801
    FASN-IN-8
    		Inhibitor
    FASN-IN-8 is a fatty acid synthase (FASN) inhibitor. FASN-IN-8 inhibits FASN-mediated de novo lipogenesis. FASN-IN-8 blocks PI3K/AKT pathway activation, inhibits cancer cells proliferation, migration and invasion. FASN-IN-8 induces apoptosis and ROS production. FASN-IN-8 can be used for the research of hepatocellular carcinoma.
    FASN-IN-8
  • HY-12364B
    (−)-C75
    		Inhibitor
    ( )-C75 is a isoform of C75 (HY-12364), which is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC50 of 35 μM. C75 is a potent CPT1A activator.
    (−)-C75
  • HY-158649
    Fasnall benzenesulfonate
    		Inhibitor
    Fasnall benzenesulfonate is the benzenesulfonate salt form of Fasnall (HY-121250). Fasnall benzenesulfonate is the inhibitor for fatty acid synthase (FASN) with IC50 of 3.7 μM. Fasnall benzenesulfonate inhibits the proliferation and induces apoptosis in breast cancer cells. Fasnall benzenesulfonate exhibits antitumor efficacy in mice.
    Fasnall benzenesulfonate
  • HY-N8495R
    4'-Hydroxyflavanone (Standard)
    		Inhibitor
    4'-Hydroxyflavanone (Standard) is the analytical standard of 4'-Hydroxyflavanone. This product is intended for research and analytical applications. 4'-Hydroxyflavanone is an inhibitor of SREBP maturation and lipid synthesis. 4'-Hydroxyflavanone is a synthetic analogue of flavanone, has potential for hepatic steatosis and dyslipidemia research[1].
    4'-Hydroxyflavanone (Standard)
Cat. No. Product Name / Synonyms Application Reactivity